← board
LITS
distress 7/10 · high distress / dilution risk$1.03+0%today-85% from 52w high
Lead: R/R AML
Revenue
pre-revenue
Liquidity
$8M
Runway
0.4 yrs
Shares 1y
-5%
Price & events
-21.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.5%
1D
+6.7%
1W
+16.3%
1M
-12.3%
3M
-18.5%
6M
-83.3%
1Y
-71.6%
2Y
-97.4%
5Y
-97.6%
All
Overview
- Market Cap
- $35.22M
- Volume
- 17.36K
- 52 Week Range
- $0.74 – $6.86
- Total Shares
- 34.03M
- Float Shares
- 26.40M
- Short %
- 0.48%
- % Held by Insiders
- 11.96%
- % Held by Institutions
- 17.32%
- RVOL
- 0.06x
- Beta
- 0.05
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- 2026-09-28earningsEarningsEarnings releaseyahoo
- December 2025readoutPhase 2voruciclib · Stage 2 topline readout of voruciclib plus venetoclax combinationSEC 8-K
- 2025-09-10partnershipGSR will provide liquidity, risk management, and strategic insight for Litecoin treasury strategy.SEC 8-K
- March 2025readoutPhase 1voruciclib · Stage 1b topline readout of voruciclib plus venetoclax combinationSEC 8-K
- December 2024readoutPhase 1voruciclib · Stage 1a topline readout of voruciclib plus venetoclax combinationSEC 8-K
- 2024-07-22trial discontinuedvoruciclib · Company intends to discontinue clinical development of voruciclibSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — R/R AML
Recent news
- 2026-06-28Lite Strategy, Inc.(NasdaqCM: LITS) added to Russell 3000E Value Benchmark - marketscreener.com
- 2026-06-27Enterprise value to revenue forward of Lite Strategy, Inc. – NASDAQ:LITS - TradingView
- 2026-06-25Director Flynn James P adds 25,000 Lite Strategy (LITS) shares - Stock Titan
- 2026-06-21LITS Q4 2024 Earnings: Significant EPS Miss Sends Stock Down Nearly 10% - ROE Trend Analysis - dars.gov.et
- 2026-06-19Lite Strategy, Inc. to Join Litecoin Foundation Summit Panel on Litecoin’s Institutional Opportunity - Quiver Quantitative
- 2026-06-19Lite Strategy takes Litecoin’s institutional push to Amsterdam - Stock Titan
- 2026-06-19Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam - GlobeNewswire
- 2026-06-18Lite Strategy Leads Strategic Investment in LitVM - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.